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Brief intervention to promote 
smoking cessation and improve 
glycemic control in smokers with 
type 2 diabetes: a randomized 
controlled trial
William H. C. Li1, M. P. Wang1, T. H. LAM2, Yannes T. Y. Cheung1, Derek Y. T. Cheung2, 
Y. N. Suen1, K. Y. Ho1, Kathryn C. B. Tan3 & Sophia S. C. CHAN1
The aim of the study was to examine the effects of a brief stage-matched smoking cessation 
intervention group compared with a control group (with usual care) in type 2 diabetes mellitus patients 
who smoked by randomized controlled trial. There were 557 patients, randomized either into the 
intervention group (n = 283) who received brief (20- minute) individualized face-to-face counseling 
by trained nurses and a diabetes mellitus-specific leaflet, or a control group (n = 274) who received 
standard care. Patient follow-ups were at 1 week, 1 month, 3 months, 6 months, and 12 months via 
telephone, and assessment of smoking status from 2012 to 2014. Patients smoked an average of 14 
cigarettes per day for more than 37 years, and more than 70% were in the precontemplation stage of 
quitting. The primary outcome showed that both the intervention and control groups had similar 7-day 
point-prevalence smoking abstinence (9.2% vs. 13.9%; p = 0.08). The secondary outcome showed that 
HbA1c levels with 7.95% [63 mmol/mol] vs. 8.05% [64 mmol/mol], p = 0.49 at 12 months, respectively. 
There was no evidence for effectiveness in promoting the brief stage-matched smoking cessation or 
improving glycemic control in smokers with type 2 diabetes mellitus, particularly those in the pre-
contemplation stage.
Diabetes mellitus (DM) is emerging as a global epidemic. By 2030, the number of patients with DM is projected to 
increase to 552 million worldwide, with one-fourth in China1. Type 2 DM constitutes more than 90% of DM cases 
among Hong Kong Chinese patients and is the leading chronic non-communicable disease and cause of death2. 
Around 10.4% of DM patients smoked in 20013. In 2012, male DM patients had a higher smoking rate (27%) 
than in the complete male population (19.1%)4. Growing evidence suggests that smoking has a substantial effect 
on morbidity and mortality rates in patients with DM5. The most common risks for DM patients who smoke are 
an increased glycated hemoglobin level (HbA1c)6, an increased incidence of hypoglycemia, and a greater risk of 
coronary heart disease, stroke, and diabetic nephropathy7–9. Smoking also increases the risk of peripheral vascular 
disease and resultant amputation in DM patients10. Given the hazardous effects of continued smoking in patients 
with DM, it is of paramount importance to help this vulnerable group to quit smoking. Nevertheless, intensive 
glycemic control and cardiovascular risk reduction are the primary objectives of treatment in patients with type 
2 DM, and only recently has the American Diabetes Association recommended smoking cessation intervention 
as a part of standard medical care11.
Medical attention for smokers with DM in outpatient clinics can serve as a site for a “teachable moment” 
because it provides opportunities for patients to initiate smoking cessation to improve their health. It also presents 
health care professionals with opportunity to advise smokers to quit while they are waiting for medical consulta-
tion or follow-up12. Nevertheless, cigarette smoking is addictive, and quitting is very difficult and has a high rate 
of relapse, particularly among chronic smokers with high nicotine dependency12–15. There are smoking cessation 
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services and guidelines provided by non-governmental organizations and hospitals locally16–18. These services are 
the major resources for smokers to seek cessation assistance and counselling.
The results of a recent qualitative study19 of smoking behavior, perceptions about quitting smoking, and fac-
tors associated with the intention to quit in Hong Kong Chinese patients with type 2 DM revealed that many 
had misconceptions about the association between DM and smoking. They did not realize the risks of continued 
smoking in relation to treatment efficacy and increased DM complications. In addition, patients claimed that 
they were satisfied with their present health status and that they saw no need to quit smoking. Some smokers even 
believed that quitting would harm their physical well-being because their bodies had become desensitized to the 
chemicals in tobacco after long-term smoking. While stage-matched smoking cessation intervention is a com-
monly used approach20–22, we found only one small randomized controlled trial (RCT) that showed an increase in 
the quit rate with 14.7% more than the usual care group after a stage-matched smoking cessation intervention in 
DM patients (95% confidence interval [CI] 8.2–21.3%, n = 280)23. The small sample sizes of fewer than100 used 
in previous studies24,25 limit the generalizability of their findings. It is imperative that there is rigorous empirical 
research on the effectiveness of stage-matched smoking cessation intervention. Our previous studies in outpatient 
clinics have revealed that patients are too impatient to undergo long-term or time-consuming intervention26. 
Cancer patients in our trial were reluctant to participate for fear that their medical consultation or procedures 
may be missed or delayed. In addition, study of DM patients showed, insufficient evidence for the efficacy of more 
intensive smoking cessation interventions such as providing a more focused counseling or interview by medical 
advisors through face-to-face or by telephone27.
Previous studies have found that smokers in Hong Kong were not ready to quit. In a trial with 1154 adult par-
ticipants who were not willing to quit, the 6-month smoking abstinence rate of unmotivated patients who received 
the usual care and self-help smoking cessation material was 10.2%28. Another trial with a group of Chinese car-
diac patient smokers (n = 1860) also showed that patients undergoing intervention with stage-matched coun-
seling failed to significantly promote their quit rate compared with the control group who received placebo 
treatments (healthy diet brief advice)29. There was no significant difference in self-reported 7-day (p = 0.60) and 
30-day (p = 0.55) abstinence between intervention and control groups29.
This study aimed to test the effectiveness of brief, stage-matched smoking cessation counseling using large 
sample sizes to promote smoking cessation and to reduce the health risks of smokers with type 2 DM. We hypoth-
esized that participants in the interventional group would (a) report higher quit rates measured by self-report and 
biochemical validation, (b) reduce smoking cigarette consumption by at least 50%; (c) report lower HbA1c levels 
than those in the control group at 12 months.
Methods
Ethical Review. This study was registered on the Clinical Controlled Trials as ISRCTN34551140 (March 5, 
2012) and approved by the Institutional Review Board of the University of Hong Kong and Hospital Authority 
Hong Kong West Cluster (April 18, 2008; Reference: UW08–142).
Written informed consent was obtained from all eligible participants. To ensure the rights of all participants 
were protected, the researchers strictly adhered to the Declaration of Helsinki and the ethical principles in design-
ing and conducting clinical research.
Study Participants. Patients who had medical follow-up visits at nine major hospital diabetes clinics and 
met the inclusion criteria were invited to participate. The inclusion criteria for the patients were (1) diagnosis of 
type 2 DM for at least 6 months, (2) age of 18 years or above, (3) smoking at least two cigarettes per day over the 
past 30 days, and (4) able to communicate in Cantonese (around 90% of the population’s language is Cantonese 
stated by the Census report in 201430). The reason for targeting patients diagnosed with type 2 DM for at least 6 
months was that their clinical condition should be more stable. Patients were excluded if they (1) were clinically 
too ill, (2) failed to have verbal response or poor cognitive state, (3) were unable to complete the questionnaires, 
and (4) were engaged in other smoking cessation programs.
Sample size. The computer programme G*Power was used to calculate the sample size31. According to the 
results of our previous study, the quit rate for smokers who were not willing to quit smoking was 10.2%28. To 
detect a rate difference of 8% (i.e., an odds ratio (OR) of about 2 for quitting smoking) in the intervention group, 
322 patients were needed in each group to achieve statistical power of 80% (commonly used in smoking cessa-
tion trials32–34) at a 5% significance level of a two-sided chi-squared test. Assuming a 15% attrition rate over the 
6-month study period35, 379 patients were required in each group to achieve a significant outcome. Hence, the 
total sample size should be 758. Assuming equal standard deviations of 1.3 in either group, the large sample size 
achieved sufficient statistical power (> 0.99) of an independent-samples t-test to detect a difference of 0.5% in the 
mean HbA1c level between the intervention group and the control group with a significance level of 5%.
Theoretical framework. Smokers may tend to reject smoking cessation intervention when they are not 
ready to quit36,37. Therefore, the use of the Stages of Change Model38, a well-known protocol for smoking cessation 
with a short 20 min intervention time can quickly access the stage of readiness of the patient and provide tailored 
smoking cessation strategies. Motivational intervention was effective in enhancing cessation rate versus control 
showed in a meta-analysis review on 31 trials from adolescents to adults (OR, 1.45; 95% CI: 1.14–1.83)39.
The transtheoretical model of behavioral change (TTM)38 was used to guide the development of the targeted 
smoking cessation intervention for smokers. It is a well-known framework in psychotherapy for behavioral 
changes and has been validated for more than 20 years40. The core constructs of the TTM include the stage of 
change, the process of change, the pros and cons of changing, and self-efficacy. Prochaska and DiClementte41 
identified various stages and processes of self-change in smoking that correspond to the five stages of change in 
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the TTM: pre- contemplation; (2) contemplation; (3) preparation stage; (4) action stage; and (5) maintenance. 
Prochaska and DiClementte41 pointed out that individuals differ in each stage of readiness to change their behav-
ior and that interventions should therefore be tailored according to the individual’s stage of change.
Interventions. The patients in the intervention group received a 20-min face-to-face individualized coun-
seling session by nurse counselors who were specifically trained for the DM smoking cessation counseling. Due 
to the short intervention time, we defined it as a brief intervention compared with the standard protocol for tele-
phone smoking cessation counseling of 35 to 45 min per session42. Studies have shown that a brief intervention 
such as oral advice or brief counseling would be cost-effective and easy to implement for physicians or nurses 
in clinic or hospital settings to promote the rate of quitting in patients43,44. Another intervention study was a 
subject-centered motivational intervention that focused on promoting the reasons to quit, on emphasizing this 
choice, on achieving goal and on the subject’s resistance to quitting45. This intervention helped to build up moti-
vations and create a comfortable atmosphere to communicate with the patients for behavioral counseling. It was 
focused on stage-matched counseling for smoking cessation that was adopted from a widely used local protocol46 
based on the clinical practice guidelines using the “Five A’s” approach, which refers to (1) asking about tobacco 
use; (2) advising quitting; (3) assessing the subject’s willingness to quit; (4) assisting in the attempt to quit; and (5) 
arranging follow-up. The approach was strongly evidence-based and confirmed the benefit of smoking cessation 
treatment in the health-care system47.
Patients in our study also received a DM-specific leaflet and a self-help pamphlet on quitting smoking. The 
leaflet summarized the relationships between smoking and diabetic complications, HbA1c levels and the com-
mon misconceptions about quitting. These relationships were emphasized in the intervention groups as a trigger 
for considering quitting. Specifically, the items stressed were smoking-related diseases, including coronary heart 
disease, peripheral vascular disease, cataracts, erectile dysfunction (for male patients), and other complications 
of DM. Thus, the intervention provided patients with the risk information of smoking towards health. Previously, 
it has been shown that health information with comprehensive context motivates persons to consider the health 
issues and enhance the perceptions of health risk48. At the 1-week and 1-month follow-up visits, in addition to 
the collection of the smoking status information, the patients received a booster of brief intervention aimed at 
enhancing their self-efficacy and overcoming their barriers to quitting. The complete follow-up visits were about 
30 min, which was similar to the baseline intervention. To ensure the nurse counsellors adhered to the interven-
tion protocol, we periodically checked the intervention process.
The control group received the usual care that focused on glucose-oriented diabetic control provided by 
DM clinics. These patients also received simple, brief advice and a self-help pamphlet on quitting smoking. In 
2010, there were 11240 hotline-counseling sessions for smoking cessation completed by the Hong Kong Hospital 
Authority (HA), and 43% of the 4156 clients who attended these clinics ceased smoking49. It is challenging for 
smokers to quit if no interventions are strategically provided to address their health issues due to the lack of con-
fidence and sustainability in implementation36,37. The HA also provides a usual care guideline for DM patients, 
which briefly mentions contacts and referral information for smoking cessation services50. Previous studies have 
shown that DM smokers are more likely to be in the pre-contemplation stage of quitting and have less interest in 
their health, which suggests that they may more likely reject smoking cessation intervention51.
Study Design. The RCT was used to examine the effectiveness of the brief intervention to promote smoking 
cessation and improve glycemic control in smokers with type 2 DM. An exhaled carbon monoxide test (≥ 4 ppm) 
was used to confirm smoking status before randomization.
The nurse counselors assigned patients to the intervention or control group individually by simple rand-
omization according to serially numbered sealed opaque envelopes containing a random number generated by 
the computer for each study site. The nurse counselors were unaware of the random sequence, which another 
researcher generated.
Study Assessments and Outcomes. The primary outcome was the self-reported 7-day point-prevalence 
smoking abstinence at 12 months. The secondary outcomes were (a) the HbA1c level at 12 months, (b) the val-
idated 12-month quit rate, (c) a reduction in smoking by at least 50% at 12 months compared with baseline, (d) 
changes in patients’ stage of readiness to quit at 12 months, and (e) the number of quit attempts over the past 12 
months.
Demographics and Smoking Characteristics. Baseline data included smoking history, demographic, 
socioeconomic, and clinical characteristics obtained from each subject using a structured questionnaire admin-
istered by a trained nurse counselor. The content of the structured questionnaire included smoking-related infor-
mation such as daily cigarette consumption, nicotine dependency as assessed by the Fagerstrom test, the stage 
of readiness to quit according to TTM, and previous quit attempts. The HbA1c levels of patients at baseline and 
during the follow-ups were obtained from their medical records.
Data Collection. The data collection period including recruitment and follow-up were between March 2012 
and April 2014.The nurse counselors conducted follow-up interviews by telephone at 1 week and 1 month after 
the initial contact. Three more follow-up telephone contacts at 3, 6, and 12 months were conducted by another 
nurse counselor who was blinded to the group assignment. The counselor collected information on smoking sta-
tus and self-efficacy52 to refrain from smoking. Information on the medical history of hospitalization in the past 3 
months and the HbA1c levels was also obtained from the respective hospitals at 3, 6, and 12 months. Patients who 
reported that they had successfully quit after 6 or 12 months or had reduced cigarette consumption by at least 50% 
at 6 months were invited to test on saliva cotinine (< 115 ng/mL NicAlert strips (www.nymox.com)53 and exhaled 
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carbon monoxide (< 4 ppm to confirm quitting or < 9 ppm for smoking reduction)54. Participants received an 
incentive offer of HK$300 (US$39) per subject to cover time cost.
Statistical Analysis. All data were analyzed using SPSS 23.0 standard version for Windows. For dichoto-
mous outcomes, a chi-squared or Fisher’s exact test was used to examine the differences between the intervention 
and control groups. The adjusted (for step-up adjustment of anti-diabetes medication) mean difference in the 
HbA1c levels at 12 months between groups was tested with the generalized linear model. An independent-samples 
t-test was used to examine the differences in the HbA1c levels between quitters and non-quitters at baseline and 
12 months. A Generalized Estimating Equation (GEE) analysis was conducted to examine changes in the HbA1c 
levels in quitters and non-quitters from baseline to 12 months adjusted to time, grouping of intervention and 
usual care, age and gender. Cessation at 6 and 12 months was compared by unadjusted odds ratios (ORs) using 
univariable logistic regression. We used an intention-to-treat analysis55. In particular, multiple imputation was 
used to compute missing data for all outcome variables, except quitting and smoking reduction. For these two 
variables, a conservative approach was adopted, in which participants who dropped out were considered to be 
unable to quit or reduce their cigarette consumption by at least 50%. Such approach has been adopted in other 
smoking cessation studies28,29.
Results
Baseline Study. Table 1 shows the baseline characteristics of the patients. Of 16,465 patients with DM who 
were screened, 890 (5.4%) were eligible and 557 (62.6%) consented. Consenting patients were randomly assigned 
to either the intervention (283 patients) or control group (274 patient). Most were male (88.3% male/11.7% 
female) and had attained secondary education or above (67.7%), and their mean age was 56 ± 11.4 years. Fewer 
patients in the intervention group (17.6%) reported having physician consultation in the past 30 days than in the 
control group (24.7%; p < 0.05). However, regression analysis showed that the higher rate of physician consulta-
tion did not predict smoking cessation at 6 and 12 months.
Other demographic characteristics including smoking, DM, and health status were similar between groups. 
Overall, participants smoked 14 cigarettes per day, and about half had moderate to severe nicotine dependence 
(Fagerstrom test score of 4 or higher). More than 70% were in the pre-contemplation stage of quitting. Although 
the mean duration since their diagnosis of DM was more than 10 years, about 80% of them perceived their health 
status as good. The 12-month retention rates for the experimental and control groups were 78.4% and 79.2%, 
respectively. A Consolidation Standards of Reporting Trials flowchart is shown in Fig. 1. Throughout the study, 
no adverse effects were reported.
Interim analysis. In April 2014, 185 of 237 (78.1%) participants in the intervention group and 185 of 
234 (79.1%) participants in the control group had been successfully evaluated at the 12-month follow-up. The 
smoking quit rate per protocol analysis for the intervention and control groups was 11.9% (22/185) and 17.3% 
(32/185), respectively, (rate ratio = 0.69, 95% CI 0.40–1.19, p = 0.17). By intention-to-treat analysis, the quit rate 
for the intervention and control groups were 9.4% and 13.7%, respectively. We stopped the recruitment early as 
the double triangular test showed that the abstinence rate with intention-to-treat analysis had achieved futility 
under the assumption that the 12-month quit rates of both groups was stable and further addition of subjects 
would not contribute to the significant changes in the results.
Intervention outcomes. The effects of the brief, stage-matched smoking cessation counseling on the pri-
mary and secondary outcomes are shown in Table 2. No statistically significant difference was seen in the 7-day 
point-prevalence of smoking abstinence, the HbA1c level, the biochemically validated quit rate, the rate of smok-
ing reduction by at least 50%, the stage of readiness to quit, or the number of quit attempts between the interven-
tion and control groups at 12 months. The results of an independent t-test showed that regardless of the group 
allocation, there was no statistically significant difference in the HbA1c levels between quitters and non-quitters 
at 12 months (Table 3). The results of GEE also showed that there were no significant differences in the changes of 
HbA1c level among quitters at each time point, but there was a significant decreased trend for non-quitters with 
OR = 0.83 (95% CI: 0.71–0.97; p = 0.022) compared to baseline after adjusting to time, grouping of intervention 
and usual care, gender and age.
Prediction factors in follow-up periods. Logistic regression showed that the intervention group had 
similar rates of abstinence at 12 months in both crude (OR, 0.63; 95% CI, 0.37–1.07) and adjusted (OR, 0.96; 95% 
CI, 0.48–1.92) models (Table 4). In the model adjusted for sociodemographic variables, quitting characteristics, 
and HbA1c level at baseline, smokers with greater daily cigarette consumption at baseline were less likely to quit 
smoking at 6 months (OR, 0.95; 95% CI, 0.91–0.99) and 12 months (OR, 0.93; 95% CI, 0.89–0.98) than those with 
lower daily cigarette consumption. Also, the smokers who attained secondary (OR, 0.40; 95% CI, 0.21–0.76) and 
post-secondary education (OR, 0.24; 95% CI, 0.07–0.87) were less likely to quit smoking at 12 months than those 
who attained a lower education level. Notably, we found that patients’ HbA1c levels at baseline could not predict 
their quitting at either 6 months (OR, 1.09; 95% CI, 0.93–1.27) or 12 months (OR, 0.92; 95% CI, 0.77–1.10).
Discussion
The present study is the largest RCT to examine the effectiveness of an intervention on smoking cessation and 
glycemic control in smokers with DM and the first study to examine an intervention that consisted of brief 
stage-matched smoking cessation counseling in Chinese patients with type 2 DM27. Our RCT design followed the 
suggestions from previous studies of smoking cessation in adults with DM7,23. The design involved the incorpo-
ration of DM-specific intervention education about the increased health risk and assessment of patients’ smoking 
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Intervention Control
n = 283 n = 274
Demographic
 Age, mean ± SD, years 56.0 ± 11.3 55.5 ± 11.5
 Male sex, n (%) 247 (87.3) 245 (89.4)
Level of education, n (%)
 Primary or below 84 (29.7) 85 (31.0)
 Secondary 170 (60.1) 156 (56.9)
 Post-secondary 24 (8.5) 27 (9.9)
 Missing 5 (1.7) 6 (2.2)
Employment status, n (%)
 Housewife 5 (1.8) 10 (3.6)
 Full time student 1 (0.4) 1 (0.4)
 Retired 83 (29.3) 74 (27.0)
 Unemployed 21 (7.4) 23 (8.4)
 Employed 173 (61.1) 166 (60.6)
Smoking history
 No. of years of regular smoking (≥ 1 cigarette per day), mean ± SD 38.1 ± 12.8 37.8 ± 12.9
 Daily cigarette consumption, mean ± SD 14.2 ± 9.0 13.5 ± 9.2
Fagerstrom test score for nicotine dependency, n (%)
 ≤ 3 (mild) 142 (50.2) 141 (51.5)
 4–5 (moderate) 85 (30.0) 93 (33.9)
 ≥ 6 (severe) 50 (17.7) 40 (14.6)
 Missing 6 (2.1) 0 (0)
Past quit attempt (quit for at least 24 hours), n (%)
 Yes 176 (62.2) 191 (69.7)
 No 107 (37.8) 83 (30.3)
Stage of readiness to quit, n (%)
 Pre-contemplation 215 (76.0) 200 (73.0)
 Contemplation 46 (16.3) 53 (19.3)
 Preparation 22 (7.8) 21 (7.7)
 Self-efficacy scorea Mean ± SD 33.0 ± 8.5 33.3 ± 8.0
DM history
 No. of years of being diagnosed with DM, mean ± SD 10.6 ± 8.3 10.2 ± 8.2
DM complicationb n (%)
 Yes 159 (56.2) 170 (62.3)
 No 118 (41.7) 103 (37.7)
 Missing 6 (2.1) 0 (0)
Health
 Hospitalized in the past 6 months, n (%) 51 (18.5) 46 (16.9)
 Doctor consultation in the past 30 days, n (%) 48 (17.6) 67 (24.7)
Self-rated health, n (%)
 Very Bad 3 (1.1) 1 (0.4)
 Bad 47 (16.6) 53 (19.3)
 Good 209 (73.9) 199 (72.3)
 Very good 1 (0.4) 2 (0.7)
 Missing 23 (8.0) 19 (7.3)
Other co-morbidities, n (%)
 Hypertension 139 (49.1) 148 (54.0)
 Cardiovascular diseases 33 (11.7) 32 (11.7)
 Respiratory diseases 12 (4.2) 14 (5.1)
 Digestive diseases 13 (4.6) 14 (5.1)
Blood Profile, mean ± SD
 HbA1c level (%) 8.1 (1.7) 8.2 (1.7)
 Low-density lipoprotein (LDL) (mmol/L) 2.6 ± 0.8 2.6 ± 0.8
 High-density lipoproteins (HDL) (mmol/L) 1.1 ± 0.4 1.1 ± 0.4
Table 1.  Baseline characteristics of the patients (N = 557). Note. aScore ranged from 12–60, the higher the 
score, the more self-efficacy the person; bDM complications refer to cardiovascular disease, stroke, neuropathy, 
eye complications, nephropathy (kidney disease), and other DM related complications.
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and smoking cessation status, including the HbA1c level after 1 year. The Bayes factor was 0.14 under the speci-
fied effect size in the power calculation (OR = 2), which supported the null hypothesis.
The overall results showed no significant differences in either the primary or the secondary outcomes between 
the intervention and control groups. There are some possible reasons for the non-significant results. Similar 
to a previous study of smoking behavior and perceptions among Hong Kong Chinese patients with type 2 
DM19, our study showed that about 80% of patients perceived their health status as good, and thus might show 
reluctance to quit. This finding is further supported by the fact that more than 70% of the patients were in the 
pre-contemplation stage of quitting. These results agree with previous studies that found that smokers with DM, 
particularly those in the pre-contemplation stage, were less likely to quit and more likely to reject smoking cessa-
tion intervention36,37.
Figure 1. The Consolidated Standards of Reporting Trial flowchart to track participants through 
randomized controlled trial. 
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Another possible reason for the non-significant results might be the large proportion of chronic or even 
“hardcore” smokers in our study. Although the definition of “hardcore” smoker has not yet been well defined, six 
characteristics have been suggested, including (a) high daily cigarette consumption (15/day or more), (b) a high 
level of nicotine dependence (Heaviness of Smoking Index of 5/6), (c) daily smoking, (d) long-term smoking 
(5 years or more of regular smoking), (e) lack of intention to quit, and (f) lack of a lifetime quit attempt56. The 
patients in our study fulfilled three of these criteria (c, d, and e) and partially fulfilled one (a). They consumed an 
average of slightly fewer than 15 cigarettes daily, but which is still higher than in the general Hong Kong popula-
tion (13 cigarettes). Most patients had attempted to quit (> 65%) and might have encountered repeated failures in 
previous quitting attempts and were perhaps discouraged after these unsuccessful experiences.
Brief advice from a physician or health care professional was found to be effective in increasing the smoking 
cessation rate in the general population57,58. Our findings are consistent with the meta-analysis in patients with 
DM in the lack of efficacy of smoking cessation intervention involving brief counseling by doctors or nurses and 
complemented by follow-up and self-help materials (eight trials with 872 participants reviewed, with a risk ratio 
of 1.32; 95%CI, 0.23–7.43)27.
The brief (20-minute) counseling session in our study, involving stage-matched and risk communication 
might not be sufficiently intensive to trigger chronic or “hardcore” smokers to quit smoking as since the daily 
cigarette consumption could reach more than 10 for both groups. Counseling for pre-contemplators was probably 
too weak, especially for those who had many past failures. Several studies have reported that hard-core smokers 
are less likely to be affected by tobacco control interventions or policies59,60.
Another possible reason for the non-significant results might be the evidence for the causality of smoking 
in DM61, which was not established at the time of the intervention. We could only explain to the patients the 
Intervention 





Primary outcome at 12 months
Self-reported 7-day quit rate 26 (9.2) 38 (13.9) 0.073 0.08
Secondary outcome
Biochemically validated quit rate, n (%)
 12 months 9 (3.2) 14 (5.1) 0.049 0.25
Self-reported reduction rateb n (%)
 3 months 29 (10.2) 46 (16.8) 0.096 0.02
 6 months 38 (13.4) 39 (14.2) 0.012 0.78
 12 months 42 (14.8) 40 (14.6) 0.003 0.94
Blood Profile
HbA1c level at 12 monthsc mean ± SE 
 % 7.95 ± 0.11 8.05 ± 0.11 − 0.41 0.49
 mmol/mol 63 ± 1.2 64 ± 1.2 − 0.38 0.49
At action stage of readiness to quit, n (%)
 3 months 22 (7.8) 17 (6.2) 0.031 0.47
 6 months 32 (11.3) 33 (12.0) 0.012 0.89
 12 months 33 (11.7) 47 (17.2) 0.078 0.12
Had quit attempt(s) for at least 24 hours since last assessment, n (%)
 3 months 41 (14.5) 44 (16.1) 0.022 0.61
 6 months 45 (15.9) 50 (18.2) 0.031 0.40
 12 months 45 (15.9) 57 (20.8) 0.063 0.14
Table 2.  Quit rate, smoking reduction rates and quit attempts in intervention and control groupsa. Note. 
aBy intention-to-treat analysis, assumed all non-responded follow-up patients as current smoker, not at action 
stage of readiness to quit and no quit attempt in past 24 hours; and bReduction by at least 50% from baseline; 
and cAdjusted for anti-diabetic medication step-up adjustment at 6-month.
Quitters (n = 64) Non-quitters (n = 493) p-value
Mean HbA1c (%)a
 12-month 7.96 7.99 0.90
 Baseline 7.94 8.17 0.32
HbA1c level changes (95% CI)b
 12-month Baseline 1.02 (0.75–1.40) 1 0.83 (0.71–0.97)* 1 /
Table 3.  Comparison of level of HbA1c (%) and changes from baseline to 12-month between 12-month 
quitters and non-quitters (N = 557). Note. aIndependent sample t-test bGeneralized Estimating Equation 
(GEE) analysis adjusted by time, grouping of intervention and usual care, gender and age. *p < 0.05.
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association—not the causation—between DM and smoking. This might have undermined the patients’ willing-
ness to quit smoking.
There is evidence that smoking is associated with increased levels of HbA1c in patients with DM6. Therefore, 
smoking cessation is hypothesized to lead to deceased HbA1c levels. The results of our study show that quitting 
smoking did not have any effect on HbA1c levels at the 12-month follow-up. One possible explanation lies in 
the difficulty of determining whether HbA1c levels could be expected to respond to smoking cessation after 12 
months. The HbA1c levels might be less responsive or might require a longer time to respond to smoking cessa-
tion. Another study from Lycett and her colleagues from a cohort study (n = 10,692 adult type 2 diabetes smok-
ers) argued that level of HbA1c increased temporarily by 0.21% at the first year of post-cessation time without 
association to weight change. The HbA1c level dropped when abstinence continued and became comparable to 
the current smokers three years later. Yet, the study did not take account for the dietary changes or exercise level 
of those quitters after smoking cessation, which may affect the rise of HbA1c level62. Indeed, previous studies 
showed that stopping smoking reduced the risk of DM6, but the beneficial effects were only apparent after 5 years 
of smoking cessation. Also, the risk of developing cardiovascular diseases would be decreased by half in quitters 
with diabetes suggested by another cohort study of 25 years follow up63.
We found that patients who smoked more cigarettes per day were less likely to quit smoking at 6 and 12 
months, which is consistent with the findings of previous studies64. Because no association was found between 
past quit attempts and the quit rate at 6 and 12 months, daily cigarette consumption could be more useful for 
health care professionals to predict the quit rate of smokers with DM.
Our findings may not be generalizable to all patients with DM, particularly for those who smoked less than 
two cigarettes per day and thus were not included in this study. We encountered difficulties in subject recruitment 
due to an unexpectedly low prevalence of smoking in our DM patients. Also, the Independent Data Monitoring 
Committee recommended, an end to subject recruitment because the interim analysis showed the futility of 
further recruitment, and thus no benefit could be expected from the intervention. The difficulties in collecting 
HbA1c data resulted in missing data across the timeline, which might have contributed to the non-significant 
findings. Nevertheless, there was only 19.1% of missing values in the whole dataset, which is considered to be 
common and acceptable in psychological studies65.
Despite the non-significant results, the findings of this study have important implications for clinical practice 
and research. The most important implications for practice relate to the smoking determination of the Hong Kong 
Chinese patients with DM. Our study adds further evidence that smokers with DM in the pre-contemplation 
stage of quitting are less likely to quit and more likely to reject smoking cessation. Therefore, it is thus of para-
mount importance to design intensive and innovative interventions that use strong warnings and clearly com-
municate the risks (and extra risks) of continued smoking as a strategy to enhance patients’ motivation to quit. 
Furthermore, approaches to promote cessation that highlight the relevance and salience of health information 
by making it personally relevant (tailored) and address the specific characteristics of patients with DM (targeted) 
are needed66. In addition, as new evidence for the causality of smoking on DM becomes established, future trials 
should clearly explain the causal effects of smoking on DM.
Variables
Odds Ratio (95% Confidence Interval)
6-month (N = 557) 12-month (N = 557)
Unadjusted model
 Control group 1.00 1.00
 Intervention group 1.00 (0.59–1.69) 0.63 (0.37–1.07)
Adjusted modela
Study group
 Control group 1.00 1.00
 Intervention group 0.97 (0.55–1.68) 0.68 (0.69–1.21)
Sex
 Male 1.00 1.00
 Female 1.4 (0.65–3.03) 1.5 (0.70–3.20)
Age 0.99 (0.97–1.02) 0.99 (0.97–1.02)
Education
 Primary or below 1.00 1.00
 Secondary 0.54 (0.28–1.05) 0.40 (0.21–0.76)
 Post-secondary 0.44 (0.14–1.39) 0.24 (0.07–0.87)
Baseline daily cigarette consumption 0.95 (0.91–0.99) 0.93 (0.89–0.98)
Baseline past quitting attempt
 No 1.00 1.00
 Yes 1.49 (0.80–2.80) 1.66 (0.88–3.13)
Baseline HbA1c level 1.09 (0.93–1.27) 0.92 (0.77–1.10)
Table 4.  Factors predicting smoking cessation at 6 and 12 months follow-up. Note. aModel adjusted for all 
the variables listed.
www.nature.com/scientificreports/
9Scientific RepoRts | 7:45902 | DOI: 10.1038/srep45902
Furthermore, because the benefits of quitting smoking, particularly the reduction in HbA1c levels, may 
require some time to respond to smoking cessation, it is recommended that future longitudinal studies be con-
ducted to detect the benefit of giving up smoking over an extended period in patients with DM.
The results show that a brief intervention is not associated with a decrease in smoking habits in DM patients. 
These patients are less likely to quit and more likely to reject smoking cessation intervention. More comprehensive 
and innovative interventions that use strong warnings and communicate clearly the risk of continued smoking as 
a strategy to enhance the motivation of smokers with DM to quit, should be tested and evaluated in future studies.
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